List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8081485/publications.pdf Version: 2024-02-01

		26630	39675
107	9,417	56	94
papers	citations	h-index	g-index
131	131	131	13411
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	CRISPR/Cas9-mediated gene knockout and interallelic gene conversion in human induced pluripotent stem cells using non-integrative bacteriophage-chimeric retrovirus-like particles. BMC Biology, 2022, 20, 8.	3.8	13
2	Targeted therapy in eosinophilic chronic obstructive pulmonary disease. ERJ Open Research, 2021, 7, 00437-2020.	2.6	13
3	Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy. Cancers, 2021, 13, 4279.	3.7	20
4	Generation of four severe early-onset chronic obstructive pulmonary disease (COPD) patient-derived induced pluripotent stem cell lines from peripheral blood mononuclear cells. Stem Cell Research, 2021, 56, 102550.	0.7	3
5	Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. Brain Communications, 2021, 3, fcab141.	3.3	17
6	Roles of Mesenchymal Cells in the Lung: From Lung Development to Chronic Obstructive Pulmonary Disease. Cells, 2021, 10, 3467.	4.1	23
7	Recurrent Genetic Abnormalities in Human Pluripotent Stem Cells: Definition and Routine Detection in Culture Supernatant by Targeted Droplet Digital PCR. Stem Cell Reports, 2020, 14, 1-8.	4.8	59
8	Les révolutions technologiques : de la prédiction au ciblage thérapeutique. Revue Des Maladies Respiratoires Actualites, 2020, 12, S55-S57.	0.0	0
9	Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine, 2020, 59, 102844.	6.1	41
10	Generation of the induced pluripotent stem cell line UHOMi002-A from peripheral blood mononuclear cells of a healthy male donor. Stem Cell Research, 2020, 49, 102037.	0.7	3
11	Pipeline for the Generation and Characterization of Transgenic Human Pluripotent Stem Cells Using the CRISPR/Cas9 Technology. Cells, 2020, 9, 1312.	4.1	7
12	Characterization of immortalized human islet stromal cells reveals a MSC-like profile with pancreatic features. Stem Cell Research and Therapy, 2020, 11, 158.	5.5	7
13	Differential long non-coding RNA expression profiles in human oocytes and cumulus cells. Scientific Reports, 2018, 8, 2202.	3.3	62
14	Concise Review: Assessing the Genome Integrity of Human Induced Pluripotent Stem Cells: What Quality Control Metrics?. Stem Cells, 2018, 36, 814-821.	3.2	51
15	Infusion of in vivo expanded cord blood lymphocytes: A new strategy to control residual disease?. Current Research in Translational Medicine, 2018, 66, 91-93.	1.8	1
16	Lung development, regeneration and plasticity: From disease physiopathology to drug design using induced pluripotent stem cells. , 2018, 183, 58-77.		18
17	Generation of the induced pluripotent stem cell line UHOMi001-A from a patient with mutations in CCDC40 gene causing Primary Ciliary Dyskinesia (PCD). Stem Cell Research, 2018, 33, 15-19.	0.7	9
18	Induced Pluripotent Stem Cells for Primary Ciliary Dyskinesia Modeling and Personalized Medicine. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 672-683.	2.9	17

#	Article	IF	CITATIONS
19	Induced pluripotent stem cells: An unlimited source of organs for transplantation. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 249-253.	1.5	1
20	Human induced pluripotent stem cells: A disruptive innovation. Current Research in Translational Medicine, 2016, 64, 91-96.	1.8	18
21	Long non-coding RNAs in human early embryonic development and their potential in ART. Human Reproduction Update, 2016, 23, 19-40.	10.8	108
22	Human–animal chimeras: ethical issues about farming chimeric animals bearing human organs. Stem Cell Research and Therapy, 2016, 7, 87.	5.5	56
23	Reinforcement of STAT3 activity reprogrammes human embryonic stem cells to naive-like pluripotency. Nature Communications, 2015, 6, 7095.	12.8	137
24	Temporal Analysis of Genome Alterations Induced by Single-Cell Passaging in Human Embryonic Stem Cells. Stem Cells and Development, 2015, 24, 653-662.	2.1	72
25	Combining DGE and RNA-sequencing data to identify new polyA+ non-coding transcripts in the human genome. Nucleic Acids Research, 2014, 42, 2820-2832.	14.5	17
26	Quality controls on cord blood unit contiguous segments: Recommendation of the SFGM-TC. Pathologie Et Biologie, 2014, 62, 218-220.	2.2	12
27	Proof of concept for AAV2/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14011.	4.1	59
28	Side Scatter Intensity Is Highly Heterogeneous in Undifferentiated Pluripotent Stem Cells and Predicts Clonogenic Self-Renewal. Stem Cells and Development, 2013, 22, 1851-1860.	2.1	23
29	Embryonic Stem Cells or Induced Pluripotent Stem Cells? A DNA Integrity Perspective. Current Gene Therapy, 2013, 13, 93-98.	2.0	47
30	Insights into human endometrial receptivity from transcriptomic and proteomic data. Reproductive BioMedicine Online, 2012, 24, 23-34.	2.4	101
31	Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood, 2012, 119, 2556-2567.	1.4	133
32	Dissecting the First Transcriptional Divergence During Human Embryonic Development. Stem Cell Reviews and Reports, 2012, 8, 150-162.	5.6	73
33	Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation. Journal of Immunology, 2011, 187, 3931-3941.	0.8	123
34	Dynamic changes in gene expression during human early embryo development: from fundamental aspects to clinical applications. Human Reproduction Update, 2011, 17, 272-290.	10.8	121
35	Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes and Development, 2011, 25, 2248-2253.	5.9	444
36	Brief Report: Benchmarking Human Pluripotent Stem Cell Markers During Differentiation Into the Three Germ Layers Unveils a Striking Heterogeneity: All Markers Are Not Equal. Stem Cells, 2011, 29, 1469-1474.	3.2	37

#	Article	IF	CITATIONS
37	Involvement of BCL2 family members in the regulation of human oocyte and early embryo survival and death: gene expression and beyond. Reproduction, 2011, 141, 549-561.	2.6	67
38	Human Cumulus Cells Molecular Signature in Relation to Oocyte Nuclear Maturity Stage. PLoS ONE, 2011, 6, e27179.	2.5	64
39	Transcriptome analysis reveals dialogues between human trophectoderm and endometrial cells during the implantation period. Human Reproduction, 2011, 26, 1440-1449.	0.9	90
40	Dialogue ovocyte-cumulus: concept et applications cliniques. , 2011, , 25-33.		0
41	1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma. EMBO Molecular Medicine, 2010, 2, 159-171.	6.9	33
42	Analysis of replication profiles reveals key role of RFC-Ctf18 in yeast replication stress response. Nature Structural and Molecular Biology, 2010, 17, 1391-1397.	8.2	112
43	Expression Map of the Human Exome in CD34+ Cells and Blood Cells: Increased Alternative Splicing in Cell Motility and Immune Response Genes. PLoS ONE, 2010, 5, e8990.	2.5	8
44	Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group. Journal of Clinical Oncology, 2010, 28, 2529-2537.	1.6	567
45	Human cumulus cells as biomarkers for embryo and pregnancy outcomes. Molecular Human Reproduction, 2010, 16, 531-538.	2.8	190
46	Controlled Ovarian Hyperstimulation for In Vitro Fertilization Alters Endometrial Receptivity in Humans: Protocol Effects1. Biology of Reproduction, 2010, 82, 679-686.	2.7	112
47	Human pluripotent stem cells: From biology to cell therapy. World Journal of Stem Cells, 2010, 2, 24.	2.8	12
48	Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFH–B cell axis. Leukemia, 2010, 24, 2080-2089.	7.2	133
49	Distinct Transcriptome Expression of the Temporal Cortex of the Primate Microcebus murinus during Brain Aging versus Alzheimer's Disease-Like Pathology. PLoS ONE, 2010, 5, e12770.	2.5	29
50	Amazonia!: An Online Resource to Google and Visualize Public Human whole Genome Expression Data. Open Bioinformatics Journal, 2010, 4, 5-10.	1.0	49
51	An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood, 2009, 114, 5173-5181.	1.4	211
52	Gene expression profile of human endometrial receptivity: comparison between natural and stimulated cycles for the same patients. Human Reproduction, 2009, 24, 1436-1445.	0.9	204
53	LH/hCGR gene expression in human cumulus cells is linked to the expression of the extracellular matrix modifying gene TNFAIP6 and to serum estradiol levels on day of hCG administration. Human Reproduction, 2009, 24, 2868-2878.	0.9	27
54	A gene expression signature shared by human mature oocytes and embryonic stem cells. BMC Genomics, 2009, 10, 10.	2.8	119

#	Article	IF	CITATIONS
55	APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer, 2009, 9, 83.	2.6	63
56	Gene expression of anti―and proâ€apoptotic proteins in malignant and normal plasma cells. British Journal of Haematology, 2009, 145, 45-58.	2.5	56
57	PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia, 2009, 23, 1989-1998.	7.2	101
58	Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nature Cell Biology, 2009, 11, 1315-1324.	10.3	445
59	Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene, 2009, 28, 3866-3879.	5.9	71
60	Embryonic stem cell markers expression in cancers. Biochemical and Biophysical Research Communications, 2009, 383, 157-162.	2.1	219
61	C/EBPA methylation is common in T-ALL but not in MO AML. Blood, 2009, 113, 1864-1866.	1.4	6
62	Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood, 2009, 113, 4331-4340.	1.4	97
63	Induction of angiogenesis by normal and malignant plasma cells. Blood, 2009, 114, 128-143.	1.4	127
64	Correlating Global Gene Regulation to Angiogenesis in the Developing Chick Extra-Embryonic Vascular System. PLoS ONE, 2009, 4, e7856.	2.5	56
65	Experimental antiâ€angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. International Journal of Cancer, 2008, 122, 2187-2198.	5.1	97
66	An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. British Journal of Haematology, 2008, 142, 802-807.	2.5	173
67	A new method for class prediction based on signed-rank algorithms applied to Affymetrix® microarray experiments. BMC Bioinformatics, 2008, 9, 16.	2.6	38
68	Total fertilization failure and molecular abnormalities in metaphase II oocytes. Reproductive BioMedicine Online, 2008, 17, 772-781.	2.4	26
69	Transcriptome of retrovirally transduced CD8+ lymphocytes: Influence of cell activation, transgene integration, and selection process. Molecular Immunology, 2008, 45, 1112-1125.	2.2	7
70	CD200: A putative therapeutic target in cancer. Biochemical and Biophysical Research Communications, 2008, 366, 117-122.	2.1	96
71	Identification of new biomarkers of human endometrial receptivity in the natural cycle. Human Reproduction, 2008, 24, 198-205.	0.9	164
72	A non-invasive test for assessing embryo potential by gene expression profiles of human cumulus cells: a proof of concept study. Molecular Human Reproduction, 2008, 14, 711-719.	2.8	189

#	Article	IF	CITATIONS
73	Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis. Journal of Immunology, 2007, 178, 3307-3315.	0.8	109
74	Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications. Clinical Cancer Research, 2007, 13, 7289-7295.	7.0	23
75	Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood, 2007, 109, 4914-4923.	1.4	132
76	ldentifying new human oocyte marker genes: a microarray approach. Reproductive BioMedicine Online, 2007, 14, 175-183.	2.4	101
77	Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes. Leukemia, 2007, 21, 230-237.	7.2	55
78	Targeting NF-κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. British Journal of Haematology, 2007, 138, 160-168.	2.5	55
79	A Meta-Analysis of Human Embryonic Stem Cells Transcriptome Integrated into a Web-Based Expression Atlas. Stem Cells, 2007, 25, 961-973.	3.2	305
80	TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica, 2007, 92, 803-811.	3.5	45
81	The human cumulus–oocyte complex gene-expression profile. Human Reproduction, 2006, 21, 1705-1719.	0.9	265
82	CD200 is a new prognostic factor in multiple myeloma. Blood, 2006, 108, 4194-4197.	1.4	205
83	Microarray-based understanding of normal and malignant plasma cells. Immunological Reviews, 2006, 210, 86-104.	6.0	56
84	Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene, 2006, 25, 7180-7191.	5.9	86
85	An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy Blood, 2006, 108, 103-103.	1.4	3
86	Heparanase Influences Expression and Shedding of Syndecan-1, and Its Expression by the Bone Marrow Environment Is a Bad Prognostic Factor in Multiple Myeloma Blood, 2006, 108, 3502-3502.	1.4	1
87	The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood, 2005, 106, 1021-1030.	1.4	245
88	Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes. Leukemia, 2005, 19, 2002-2005.	7.2	35
89	Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene, 2005, 24, 3512-3524.	5.9	97
90	A Multi-Center and Multi-National Program To Assess the Clinical Accuracy of the Molecular Subclassification of Leukemia by Gene Expression Profiling Blood, 2005, 106, 757-757.	1.4	7

#	Article	IF	CITATIONS
91	Molecular Classification of Multiple Myeloma (MM) Based on Gene Expression Profiling (GEP) and Fluorescence In Situ Hybridisation (FISH) Is an Independent Predictor for Event Free Survival (EFS) Blood, 2005, 106, 507-507.	1.4	4
92	Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. European Cytokine Network, 2005, 16, 57-64.	2.0	23
93	An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti–IL-6 antibody-induced apoptosis. Blood, 2004, 103, 1829-1837.	1.4	65
94	Cytokines in Multiple Myeloma. , 2004, , 69-91.		1
95	Survival and Proliferation Factors of Normal and Malignant Plasma Cells. International Journal of Hematology, 2003, 78, 106-113.	1.6	195
96	A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene, 2003, 22, 2950-2959.	5.9	139
97	Comparison of Murine Leukemia Virus, Human Immunodeficiency Virus, and Adeno-Associated Virus Vectors for Gene Transfer in Multiple Myeloma: Lentiviral Vectors Demonstrate a Striking Capacity to Transduce Low-Proliferating Primary Tumor Cells. Human Gene Therapy, 2003, 14, 1727-1739.	2.7	14
98	Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood, 2003, 102, 592-600.	1.4	190
99	Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood, 2002, 100, 1113-1122.	1.4	131
100	Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene, 2002, 21, 2584-2592.	5.9	58
101	Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene, 2002, 21, 6848-6857.	5.9	157
102	Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood, 2002, 100, 1113-22.	1.4	59
103	Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood, 2001, 98, 771-780.	1.4	154
104	JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. British Journal of Haematology, 2000, 109, 823-828.	2.5	146
105	Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death and Differentiation, 2000, 7, 1244-1252.	11.2	125
106	Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia, 2000, 14, 188-197.	7.2	56
107	Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb International Immunology, 1998, 10, 1881-1889.	4.0	23